Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial

Trials
15 November 2021
https://pubmed.ncbi.nlm.nih.gov/34781989/

The EMF Toxicity Epidemic - Protection and Treatment - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Longevity - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Autoimmune thyroiditis Part 3 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 3 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness. This last segment will bring it all together and give practical ways to use this information. 

Autoimmune thyroiditis Part 2 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 2 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness

Autoimmune thyroiditis Part 1 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Strategies for reducing excess body fat... - Jill Brook, MA (2021 Conference) (LDN, low dose naltrexone)

PTSD and other mental health treatment with opioid antagonist... - Galyn Forster, MS, LPC (2021 Conference) (LDN, low dose naltrexone)

Henoch-Schonlein Purpura - Sally Daughtrey, ND (2021 Conference) (LDN, low dose naltrexone)

In her presentation, Dr. Daughtry explains Henoch-Schonlein (HSP), its triggers and complications (such as serious hidden infections often missed initially), and the use of Low Dose Naltrexone in treating HSP. Dr. Daughtry gives an in-depth look into one pediatric case she treated successfully with LDN.